Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites

Evidence-based Complementary and Alternative Medicine

Volumn 2016, Issue , 2016, Pages

  Chen, Xiao Jia ^a   Zhang, Xiao Jing ^a   Shui, Yan Mei ^b   Wan, Jian Bo ^a   Gao, Jian Li ^b  

^a University of Macau   (Macao)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GINSENOSIDE; PROTOPANAXADIOL; SAPONIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; DRUG EFFECT; DRUG METABOLISM; HUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

EID: 84982824732     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2016/5738694     Document Type: Review

References (200)

1. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015, " CA Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5-29, 2015.
2. W. Chen, R. Zheng, H. Zeng, S. Zhang, and J. He, "Annual report on status of cancer in China, 2011, " Chinese Journal of Cancer Research, vol. 27, no. 1, pp. 2-12, 2015.
3. L. S. Shen, Bencao Gangmu, Huaxia, Beijing, China, 1st edition, 2005.
4. The State Pharmacopoeia Commission of People's Republic of China, Pharmacopoeia of the People's Republic of China, Chemical Industry Press, Beijing, China, 2000.
5. State Administration of Traditional Chinese Medicine, ZhongHua BenCao JinXuan Ben, Shanghai Science andTechnology, Shanghai, China, 1996.
6. B. Cao, Y. Qi, Y. Yang et al., "20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer, " PLoS ONE, vol. 9, no. 11, article e111201, 2014.
7. H. Dong, L.-P. Bai, V. K. W. Wong et al., "The in vitro structure-related anti-cancer activity of ginsenosides and their derivatives, " Molecules, vol. 16, no. 12, pp. 10619-10630, 2011.
8. K. S. Kang, T. Yokozawa, N. Y. Yamabe, H. Y. Kim, and J. H. Park, "ESR study on the structure and hydroxyl radical-scavenging activity relationships of ginsenosides isolated from Panax ginseng C. A. Meyer, " Biological and Pharmaceutical Bulletin, vol. 30, no. 5, pp. 917-921, 2007.
9. J.-B. Wan, S. M.-Y. Lee, J.-D. Wang et al., "Panax notoginseng reduces atherosclerotic lesions inApoE-deficient mice and inhibits TNF- -induced endothelial adhesion molecule expression and monocyte adhesion, " Journal of Agricultural and Food Chemistry, vol. 57, no. 15, pp. 6692-6697, 2009.
10. S. Sengupta, S.-A. Toh, L. A. Sellers et al., "Modulating angiogenesis: the yin and the yang in ginseng, " Circulation, vol. 110, no. 10, pp. 1219-1225, 2004.
11. A. Rhule, S. Navarro, J. R. Smith, and D. M. Shepherd, "Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264. 7 cells, " Journal of Ethnopharmacology, vol. 106, no. 1, pp. 121-128, 2006.
12. S. Shibata, "Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds, " Journal of Korean Medical Science, vol. 16, pp. S28-S37, 2001.
13. W. Wang, G.-J. Wang, H.-T. Xie et al., "Determination of ginsenoside Rd in dog plasma by liquid chromatography-mass spectrometry after solid-phase extraction and its application in dog pharmacokinetics studies, " Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 852, no. 1-2, pp. 8-14, 2007.
14. P. Y. K. Yue, N. K. Mak, Y. K. Cheng et al., "Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides, " Chinese Medicine, vol. 2, article 6, 2007.
15. S. H. Shim, K.-H. Baek, and Y. S. Kim, "Inhibition of human 20S proteasome by ginsenosides fromPanax ginseng, " Bulletin of the Korean Chemical Society, vol. 30, no. 6, pp. 1385-1387, 2009.
16. A. G. Musende, A. Eberding, C. A. Wood et al., "A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer, " Anti-Cancer Drugs, vol. 23, no. 5, pp. 543-552, 2012.
17. H. Hasegawa, "Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid, " Journal of Pharmacological Sciences, vol. 95, no. 2, pp. 153-157, 2004.
18. W. Li, Y. Liu, J. W. Zhang et al., "Anti-androgen-independent prostate cancer effects of ginsenoside metabolites In vitro: mechanism and possible structure-activity relationship investigation, " Archives of Pharmacal Research, vol. 1, pp. 49-57, 2009.
19. Q. Mao, P.-H. Zhang, Q. Wang, and S.-L. Li, "Ginsenoside F2 induces apoptosis in humor gastric carcinoma cells through reactive oxygen species-mitochondria pathway andmodulation of ASK-1/JNK signaling cascade in vitro and in vivo, " Phytomedicine, vol. 21, no. 4, pp. 515-522, 2014.
20. J. I. Lee, Y. W. Ha, T. W. Choi et al., "Cellular uptake of ginsenosides in Korean white ginseng and red ginseng and their apoptotic activities in human breast cancer cells, " Planta Medica, vol. 77, no. 2, pp. 133-140, 2011.
21. J. Jin, S. Shahi, H. K. Kang, H. W. van Veen, and T.-P. Fan, "Metabolites of ginsenosides as novel BCRP inhibitors, " Biochemical and Biophysical Research Communications, vol. 345, no. 4, pp. 1308-1314, 2006.
22. D.-F. Toh, D. N. Patel, E. C. Y. Chan, A. Teo, S.-Y. Neo, and H.-L. Koh, "Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells, " Chinese Medicine, vol. 6, article 4, 2011.
23. Y.-W. Lin, Y.-C. Mou, C.-C. Su, and B.-H. Chiang, "Antihepatocarcinoma activity of lactic acid bacteria fermented Panax notoginseng, " Journal of Agricultural and Food Chemistry, vol. 58, no. 15, pp. 8528-8534, 2010.
24. X. Liu, L. Qiao, D. Xie et al., "Microbial transformation of ginsenoside-Rg 1 by Absidia coerulea and the reversal activity of the metabolites towards multi-drug resistant tumor cells, " Fitoterapia, vol. 82, no. 8, pp. 1313-1317, 2011.
25. E.-A. Bae, J.-E. Shin, and D.-H. Kim, "Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect, " Biological and Pharmaceutical Bulletin, vol. 28, no. 10, pp. 1903-1908, 2005.
26. M. Han, J.-G. Hou, C.-M. Dong et al., "Isolation, synthesis and structures of ginsenoside derivatives and their anti-tumor bioactivity, " Molecules, vol. 15, no. 1, pp. 399-406, 2010.
27. Z.-G. Yang, H.-X. Sun, and Y.-P. Ye, "Ginsenoside Rd from Panax notoginseng is cytotoxic towards HeLa cancer cells and induces apoptosis, " Chemistry and Biodiversity, vol. 3, no. 2, pp. 187-197, 2006.
28. G.-Y. Liu, X. Bu, H. Yan, and W. W.-G. Jia, "20S-Protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and-independent pathways, " Journal of Natural Products, vol. 70, no. 2, pp. 259-264, 2007.
29. G.-Y. Zhu, Y.-W. Li, A. K.-W. Tse et al., "20(S)-Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells, " European Journal of Pharmacology, vol. 668, no. 1-2, pp. 88-98, 2011.
30. D. G. PopovichandD. D. Kitts, "Structure-functionrelationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line, " Archives of Biochemistry and Biophysics, vol. 406, no. 1, pp. 1-8, 2002.
31. L. H. Sun, Q. Wang, X. M. Liu et al., "Anti-cancer effects of 20(S)-protopanoxadiol on human acute lymphoblastic leukemia cell lines Reh and RS4;11, " Medical Oncology, vol. 28, no. 3, pp. 813-821, 2011.
32. W. Wang, E. R. Rayburn, J. Hang, Y. Q. Zhao, H. Wang, and R. W. Zhang, "Anti-lung cancer effects of novel ginsenoside 25-OCH3-PPD, " Lung Cancer, vol. 65, no. 3, pp. 306-311, 2009.
33. X. Bi, Y. Zhao, W. Fang, and W. Yang, "Anticancer activity of Panax notoginseng extract 20(S)-25-OCH3-PPD: Targetting -catenin signalling, " Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 11, pp. 1074-1078, 2009.
34. Y.-L. Wu, Y. Wan, X.-J. Jin et al., "25-OCH3-PPD induces the apoptosis of activated t-HSC/Cl-6 cells via c-FLIP-mediated NF- B activation, " Chemico-Biological Interactions, vol. 194, no. 2-3, pp. 106-112, 2011.
35. W. Wang, H. Wang, E. R. Rayburn, Y. Zhao, D. L. Hill, and R. Zhang, "20(S)-25-methoxyl-dammarane-3 , 12 , 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action, " British Journal of Cancer, vol. 98, no. 4, pp. 792-802, 2008.
36. T. Akao, M. Kanaoka, and K. Kobashi, "Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration: measurement of compound K by enzyme immunoassay, " Biological & Pharmaceutical Bulletin, vol. 21, no. 3, pp. 245-249, 1998.
37. W. Zhou, M.-Q. Feng, J.-Y. Li, and P. Zhou, "Studies on the preparation, crystal structure and bioactivity of ginsenoside compound K, " Journal of Asian Natural Products Research, vol. 8, no. 6, pp. 519-527, 2006.
38. K. Suda, K. Murakami, J. Murata, H. Hasegawa, and I. Saiki, "An intestinal bacterial metabolite (M1) of ginseng protopanaxadiol saponins inhibits tumor-induced neovascularization, " Wakan Iyakugaku Zasshi, vol. 17, no. 4, pp. 144-150, 2000.
39. H. Hasegawa, "Metabolic activation of ginsenoside against cancer: intestinal bacterial deglycosylation and hepatic fattyacid esterification, " Wakan Iyakugaku Zasshi, vol. 18, no. 6, pp. 217-228, 1997.
40. A. D. Kim, K. A. Kang, R. Zhang et al., "Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through themodulation of AMP-activated protein kinase, " Environmental Toxicology and Pharmacology, vol. 30, no. 2, pp. 134-140, 2010.
41. H. W. Yim, H.-S. Jong, Y. K. Tai et al., "Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis, " Cancer Research, vol. 65, no. 5, pp. 1952-1960, 2005.
42. C. Hu, G. Song, B. Zhang et al., "Intestinal metabolite compound K of panaxoside inhibits the growth of gastric carcinoma by augmenting apoptosisviaBid-mediated mitochondrial pathway, " Journal of Cellular and Molecular Medicine, vol. 16, no. 1, pp. 96-106, 2012.
43. S.-H. Cho, K.-S. Chung, J.-H. Choi, D.-H. Kim, and K.-T. Lee, "Compound K, a metabolite of ginseng saponin, induces apoptosis via caspase-8-dependent pathway in HL-60 human leukemia cells, " BMC Cancer, vol. 9, article 149, pp. 449-461, 2009.
44. K. A. Kang, Y. W. Kim, and S. U. Kim, "G1 phase arrest of the cell cycle by a ginseng metabolite, compound K, inU937 human monocytic leukamia cells, " Archives of Pharmacal Research, vol. 28, no. 6, pp. 685-690, 2005.
45. I. Saiki, "In vivo anti-metastatic action in ginseng saponins is based on their intestinal bacterial metabolites after oral administration, " Journal of Ginseng Research, vol. 31, no. 1, pp. 1-13, 2007.
46. X. Wang and Y. Wang, "Ginsenoside Rh2 mitigates pediatric leukemia through suppression of Bcl-2 in leukemia cells, " Cellular Physiology and Biochemistry, vol. 37, no. 2, pp. 641-650, 2015.
47. S. Liu, M. Chen, P. Li et al., "Ginsenoside Rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma, " Cellular Physiology and Biochemistry, vol. 36, no. 2, pp. 499-508, 2015.
48. J.-L. Gao, G.-Y. Lv, B.-C. He et al., "Ginseng saponin metabolite 20(S)-protopanaxadiol inhibits tumor growth by targetingmultiple cancer signaling pathways, " Oncology Reports, vol. 30, no. 1, pp. 292-298, 2013.
49. J.-W. Hwang, Y.-M. Baek, I.-S. Jang et al., "An enzymatically fortified ginseng extract inhibits proliferation and induces apoptosis of KATO3 human gastric cancer cells via modulation of Bax, mTOR, PKB and I B , "MolecularMedicine Reports, vol. 11, no. 1, pp. 670-676, 2015.
50. Y.-L. Zhang, R. Zhang, H.-L. Xu, X.-F. Yu, S.-C. Qu, and D.-Y. Sui, "20(S)-protopanaxadiol triggers mitochondrial-mediated apoptosis in human lung adenocarcinoma A549 cells via inhibiting the PI3K/Akt signaling pathway, " The American Journal of Chinese Medicine, vol. 41, no. 5, pp. 1137-1152, 2013.
51. Y. Yu, Q. Zhou, Y. Hang, X. Bu, and W. Jia, "Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells, " Cancer, vol. 109, no. 11, pp. 2374-2382, 2007.
52. H. H. Choi, H.-S. Jong, J.-H. Park et al., "A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells, " International Journal of Oncology, vol. 23, no. 4, pp. 1087-1093, 2003.
53. S. Park, H.-J. Lee, S.-J. Jeong et al., "Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells, " Food and Chemical Toxicology, vol. 49, no. 6, pp. 1367-1372, 2011.
54. B.-C. He, J.-L. Gao, X. Luo et al., "Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ -catenin signaling, " International Journal ofOncology, vol. 38, no. 2, pp. 437-445, 2011.
55. J.-H. Yoon, Y.-J. Choi, S.-W. Cha, and S.-G. Lee, "Anti-metastatic effects of ginsenoside Rd via inactivation of MAPK signaling and induction of focal adhesion formation, " Phytomedicine, vol. 19, no. 3-4, pp. 284-292, 2012.
56. N. Riaz, L. G. Morris, W. Lee, and T. A. Chan, "Unraveling the molecular genetics of head and neck cancer through genomewide approaches, " Genes and Diseases, vol. 1, no. 1, pp. 75-86, 2014.
57. Z. Zhang, G.-J. Du, C.-Z. Wang et al., "Compound K, a ginsenoside metabolite, inhibits colon cancer growth via multiple pathways including p53-p21 interactions, " International Journal of Molecular Sciences, vol. 14, no. 2, pp. 2980-2995, 2013.
58. S. J. Hwang, J. Y. Cha, S. G. Park et al., "Diol-and triol-type ginseng saponins potentiate the apoptosis of NIH3T3 cells exposed to methyl methanesulfonate, " Toxicology and Applied Pharmacology, vol. 181, no. 3, pp. 192-202, 2002.
59. J. S. Kim, E. J. Joo, J. Chun et al., "Induction of apoptosis by ginsenoside Rk1 in SK-MEL-2-human melanoma, " Archives of Pharmacal Research, vol. 35, no. 4, pp. 717-722, 2012.
60. S.-E. Kim, Y. H. Lee, J. H. Park, and S. K. Lee, "Ginsenoside-Rs3, a new diol-type ginseng saponin, selectively elevates protein levels of p53 and p21(WAF1) leading to induction of apoptosis in SK-HEP-1 cells, " Anticancer Research, vol. 19, no. 1, pp. 487-491, 1999.
61. S. Sin, S. Y. Kim, and S. S. Kim, "Chronic treatment with ginsenoside Rg3 induces Akt-dependent senescence in human glioma cells, " International Journal of Oncology, vol. 41, no. 5, pp. 1669-1674, 2012.
62. Y.-J. Choi, L.-J. Kang, and S.-G. Lee, "Stimulation of DDX3 expression by ginsenoside Rg3 through the Akt/p53 pathway activates the innate immune response via TBK1/IKK /IRF3 signalling, "CurrentMedicinal Chemistry, vol. 21, no. 8, pp. 1050-1060, 2014.
63. X. Shan, Y.-S. Fu, F. Aziz, X.-Q. Wang, Q. Yan, and J.-W. Liu, "Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation, " PLoS ONE, vol. 9, no. 12, article e115401, 2014.
64. B. Li, J. Zhao, C.-Z. Wang et al., "Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53, " Cancer Letters, vol. 301, no. 2, pp. 185-192, 2011.
65. C.-C. Cheng, S.-M. Yang, C.-Y. Huang, J.-C. Chen, W.-M. Chang, and S.-L. Hsu, "Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells, " Cancer Chemotherapy and Pharmacology, vol. 55, no. 6, pp. 531-540, 2005.
66. X.-X. Guo, Y. Li, C. Sun et al., "p53-dependent Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells, " Protein and Cell, vol. 5, no. 3, pp. 224-234, 2014.
67. Y. Usami, Y.-N. Liu, A.-S. Lin et al., "Antitumor agents. 261. 20(S)-protopanaxadiol and 20(S)-protopanaxatriol as antiangiogenic agents and total assignment of 1H NMR spectra, " Journal of Natural Products, vol. 71, no. 3, pp. 478-481, 2008.
68. A. Jeong, H.-J. Lee, S.-J. Jeong et al., "CompoundKinhibits basic fibroblast growth factor-induced angiogenesis via regulation of p38 mitogen activated protein kinase and AKT in human umbilical vein endothelial cells, " Biological & Pharmaceutical Bulletin, vol. 33, no. 6, pp. 945-950, 2010.
69. T. Ota, M. Maeda, and S. Odashima, "Mechanism of action of ginsenoside Rh2: uptake and metabolism of ginsenoside Rh2 by cultured B16 melanoma cells, " Journal of Pharmaceutical Sciences, vol. 80, no. 12, pp. 1141-1146, 1991.
70. Y. H. Jin, H. Yim, J. H. Park, and S. K. Lee, "Cdk2 activity is associated with depolarization of mitochondrial membrane potential during apoptosis, " Biochemical and Biophysical Research Communications, vol. 305, no. 4, pp. 974-980, 2003.
71. C.-Z. Wang, B. Li, X.-D. Wen et al., "Paraptosis and NF- B activation are associated with protopanaxadiol-induced cancer chemoprevention, " BMC Complementary and Alternative Medicine, vol. 13, article 2, 2013.
72. M.-T. Park, H.-J. Cha, J.-W. Jeong et al., "Glucocorticoid receptor-induced down-regulation of MMP-9 by ginseng components, PD and PT contributes to inhibition of the invasive capacity of HT1080 human fibrosarcoma cells, " Molecules and Cells, vol. 9, no. 5, pp. 476-483, 1999.
73. G. Li, Z. H. Wang, Y. X. Sun, K. Liu, and Z. R. Wang, "Ginsenoside 20(S)-protopanaxadiol inhibits the proliferation and invasion of human fibrosarcoma HT1080 cells, " Basic and Clinical Pharmacology and Toxicology, vol. 98, no. 6, pp. 588-592, 2006.
74. Y. Liu, G. Yang, X. Buet al., "Cell-type-specific regulationof raftassociated Akt signaling, " Cell Death and Disease, vol. 2, no. 4, article e145, 2011.
75. G.-J. Du, C.-Z. Wang, Z.-Y. Zhang et al., "Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells, " Journal of Pharmacy and Pharmacology, vol. 64, no. 5, pp. 727-734, 2012.
76. B. Park, Y.-M. Lee, J.-S. Kim et al., "Neutral sphingomyelinase 2 modulates cytotoxic effects of protopanaxadiol on different human cancer cells, " BMC Complementary and Alternative Medicine, vol. 13, article 194, 2013.
77. Y. Zhao, L. Bu, H. Yan, and W. Jia, "20S-protopanaxadiol inhibits P-glycoprotein in multidrug resistant cancer cells, " Planta Medica, vol. 75, no. 10, pp. 1124-1128, 2009.
78. J. H. Cheong, H. Kim, M. J. Hong et al., "Stereoisomer-specific anticancer activities of ginsenoside Rg3 and Rh2 inHepG2 cells: disparity in cytotoxicity and autophagy-inducing effects due to 20(S)-epimers, " Biological and Pharmaceutical Bulletin, vol. 38, no. 1, pp. 102-108, 2015.
79. Y.-H. Zhang, H.-D. Li, B. Li, S.-D. Jiang, and L.-S. Jiang, "Ginsenoside Rg3 induces DNA damage in human osteosarcoma cells and reduces MNNG-induced DNA damage and apoptosis in normal human cells, " Oncology Reports, vol. 31, no. 2, pp. 919-925, 2014.
80. B.-S. Wang, L.-S. Zhang, D.-M. Song, J.-H. Zhang, and Y.-M. Liu, "Effect of gensenoside Rg3 on apoptosis of Hep-2 and expression of HIF-1alha in human laryngeal cancer cell line under anoxic conditions, " Journal of Chinese Medicinal Materials, vol. 32, no. 1, pp. 102-106, 2009.
81. J.-H. Wang, J.-F. Nao, M. Zhang, and P. He, "20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancerHO-8910 cells through PI3K/Akt and XIAP pathways, " Tumor Biology, vol. 35, no. 12, pp. 11985-11994, 2014.
82. H.-S. Kim, E.-H. Lee, S.-R. Ko, K.-J. Choi, J.-H. Park, and D.-S. Im, "Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells, " Archives of Pharmacal Research, vol. 27, no. 4, pp. 429-435, 2004.
83. Q.-J. Chen, M.-Z. Zhang, and L.-X. Wang, "Gensenoside Rg3 inhibits hypoxia-induced VEGF expression in human cancer cells, " Cellular Physiology and Biochemistry, vol. 26, no. 6, pp. 849-858, 2010.
84. W. Y. Ng and M. S. Yang, "Effects of ginsenosides Re and Rg3 on intracellular redox state and cell proliferation in C6 glioma cells, " Chinese Medicine, vol. 3, article 8, 2008.
85. H.-B. Tang, Y.-P. Ren, J. Zhang, S.-H. Ma, F. Gao, and Y.-P. Wu, "Correlation of insulin-like growth factor-1 (IGF-1) to angiogenesis of breast cancer in IGF-1-deficient mice, " Chinese Journal of Cancer, vol. 26, no. 11, pp. 1215-1220, 2007.
86. X. Wang, Y.-L. Zheng, K. Li, N. Lin, and Q.-X. Fan, "The effects of ginsenosides Rg3 on the expressions of VEGF and KDR in human lung squamous cancer cells, " Journal of Chinese medicinal materials, vol. 32, no. 11, pp. 1708-1710, 2009.
87. H. Tao, M. Yao, S. Zou, D. Zhao, and H. Qiu, "Effect of angiogenesis inhibitor Rg3 on the growth and metastasis of gastric cancer in SCID mice, " ZhonghuaWai Ke Za Zhi, vol. 40, no. 8, pp. 606-608, 2002.
88. J.-W. Kim, S.-Y. Jung, Y.-H. Kwon et al., "Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells, " Cancer Biology and Therapy, vol. 13, no. 7, pp. 504-515, 2012.
89. X. Shan, F. Aziz, L. L. Tian, X. Q. Wang, Q. Yan, and J. W. Liu, "Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression, " International Journal of Oncology, vol. 46, no. 4, pp. 1667-1676, 2015.
90. X. Jiang, Y. Xin, T.-M. Xu, and Y.-Q. Qu, "Effects of ginsenoside Rg3 on the invasion andmetastasis ofmouse melanoma cell line B16 as well as the expression of MMP-9, " Tumor, vol. 31, no. 2, pp. 117-121, 2011.
91. Y. Yu, G.-M. Zhang, J. Su, L.-H. Shang, and G. Chen, "Effects of ginsenoside Rg3 on the micro-lymphatic metastasis of colorectal neoplasms, " Chinese Journal of Oncology, vol. 27, no. 12, p. 742, 2005.
92. T. Liu, L. Zhao, Y. Zhang et al., "Ginsenoside 20(S)-Rg3 targets HIF-1 to Block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells, " PLoS ONE, vol. 9, no. 9, Article ID e103887, 2014.
93. J.-B. He, H.-Z. Liao, and Y.-Q. Zhang, "Ginsenoside Rg3 reverses multidrug resistance of lung adenocarcinoma in mice, " Journal of Practical Oncology, vol. 27, no. 4, pp. 373-378, 2012.
94. B.-S. Sun, X.-L. Liu, L.-L. Liu, S.-B. Fu, Z.-F. Wu, and S.-L. Gong, "Suppressive effects of ginsenoside Rg3 combined with X-ray irradiation on growth of melanoma cells, " Journal of Jilin University Medicine Edition, vol. 32, no. 6, pp. 1016-1018, 2006.
95. N. Nie, X.-L. Wu, H.-C. Luo, B. Liu, and Q. Liu, "Inhibitoryeffect of 5-fluorouracil combined with Rg3 on proliferation of gastric cancer cells, " Journal of Shanghai Jiaotong University (Medical Science), vol. 34, no. 5, pp. 645-649, 2014.
96. C.-K. Lee, K.-K. Park, A.-S. Chung, and W.-Y. Chung, "Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species, " Food and Chemical Toxicology, vol. 50, no. 7, pp. 2565-2574, 2012.
97. S.-S. Kim, S. Seong, and S.-Y. Kim, "Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells, " Oncology Letters, vol. 7, no. 4, pp. 1265-1269, 2014.
98. L.-Q. Yang, B. Wang, H. Gan et al., "Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo, " Biopharmaceutics & Drug Disposition, vol. 33, no. 8, pp. 425-436, 2012.
99. X.-H. Xu, J.-B. He, and P. Zhang, "Effects of Ginsenoside Rg3 in combination with Suramin on growth of lung cancer in mice, " Chinese Journal of Cancer Prevention and Treatment, vol. 20, no. 2, pp. 97-101, 2013.
100. J.-B. Che, Z.-H. Liu, H.-B. Ma et al., "Influence of As2O3 combined with ginsenosides Rg3 on inhibition of lung cancer NCI-H1299 cells and on subsistence of nude mice bearing hepatoma, " Asian Pacific Journal of TropicalMedicine, vol. 7, no. 10, pp. 772-775, 2014.
101. R. Wu, Q. Ru, L. Chen, B. Ma, and C. Li, "Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22-bearing mice, " Journal of Food Science, vol. 79, no. 7, pp. H1430-H1435, 2014.
102. P. Lu, W. Su, Z.-H. Miao, H.-R. Niu, and Q.-L. Hua, "Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer, " Chinese Journal of Integrative Medicine, vol. 14, no. 1, pp. 33-36, 2008.
103. T.-K. Yun, "Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds, " Mutation Research- Fundamental and Molecular Mechanisms of Mutagenesis, vol. 523-524, pp. 63-74, 2003.
104. Y.-S. Keum, S.-S. Han, K.-S. Chun et al., "Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF- B activation and tumor promotion, " Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, vol. 523-524, pp. 75-85, 2003.
105. T. Ota, M. Maeda, S. Odashima, J. Ninomiya-Tsuji, and M. Tatsuka, "G1 phase-specific suppression of the Cdk2 activity by ginsenoside Rh2 in cultured murine cells, " Life Sciences, vol. 60, no. 2, pp. PL39-PL44, 1996.
106. X.-L. Zeng and Z.-G. Tu, "Effects of ginsenoside Rh2 on signal transduction in hepatocarcinoma SMMC-7721 cells, " Chinese Journal of Hepatology, vol. 12, no. 9, pp. 565-566, 2004.
107. W. Ge and S.-J. Yang, "Molecularmechanism of G-Rh2-induced apoptosis in gastric carcinoma cells, " World Chinese Journal of Digestology, vol. 15, no. 28, pp. 2972-2976, 2007.
108. H. Yu, J. Hou, X. Qi, Y. Shi, S. Li, and C. Zhang, "20 (S)-ginsenoside-Rh2 induces apoptosis in human lung adenocarcinoma A549 cells by activating NF- B signaling pathway, " Journal of Pure and Applied Microbiology, vol. 7, no. 1, pp. 287-294, 2013.
109. Z.-M. You, L. Zhao, J. Xia et al., "Down-regulation of phosphoglucose isomerase/autocrine motility factor enhances gensenoside Rh2 pharmacological action on leukemia KG1 cells, " Asian Pacific Journal of Cancer Prevention, vol. 15, no. 3, pp. 1099-1104, 2014.
110. N. Wu, G.-C. Wu, R. Hu, M. Li, and H. Feng, "GinsenosideRh2 inhibits glioma cell proliferation by targeting microRNA-128, " Acta Pharmacologica Sinica, vol. 32, no. 3, pp. 345-353, 2011.
111. M.-J. Kim, H. Yun, D.-H. Kim et al., "Amp-activated protein kinase determines apoptotic sensitivity of cancer cells to ginsenoside-Rh2, " Journal of Ginseng Research, vol. 38, no. 1, pp. 16-21, 2014.
112. S. Li, Y. Gao, W. Ma et al., "EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2, " Tumor Biology, vol. 35, no. 6, pp. 5593-5598, 2014.
113. W. Chen and Y. Qiu, "Ginsenoside Rh2 targets EGFR by upregulation of miR-491 to enhance anti-tumor activity in hepatitis B virus-related hepatocellular carcinoma, " Cell Biochemistry and Biophysics, vol. 72, no. 2, pp. 325-331, 2015.
114. Q. Zhang, B. Hong, S. Wu, and T. Niu, "Inhibition of prostatic cancer growth by ginsenoside Rh2, " Tumor Biology, vol. 36, no. 4, pp. 2377-2381, 2015.
115. H.-K. Yang, Y.-H. Lü, H.-D. Liu et al., "Effect of ginsenoside Rh2 on VEGF-C and lymphangiogenesis in the mouse-transplanted tumor, " Acta Anatomica Sinica, vol. 40, no. 2, pp. 265-268, 2009.
116. Q. Li, X.-Y. Wang, Y. Li, and Y.-H. Jin, "Mechanism of ginsenoside Rh2 in enhancing sensitivity of human liver cancer HepG2 cells to betulinic acid, " Chinese Journal of Biologicals, vol. 24, no. 5, pp. 531-542, 2011.
117. A. G. Musende, A. Eberding, W. Jia, E. Ramsay, M. B. Bally, and E. T. Guns, "Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer, " Prostate, vol. 70, no. 13, pp. 1437-1447, 2010.
118. H. Zhang, H.-Q. Wang, H.-L. Zhang, D. Kong, and X.-Z. Wu, "Ginsenoside Rh2 reverses P-glycoprotein-mediated multidrug resistance ofMCF-7/ADMcells, " Tumor, vol. 27, no. 5, pp. 365-369, 2007.
119. J. Y. Cho, E. S. Yoo, K. U. Baik, M. H. Park, and B. H. Han, "In vitro inhibitory effect of protopanaxadiol ginsenosides on tumor necrosis factor (TNF)- production and its modulation by known TNF- antagonists, " Planta Medica, vol. 67, no. 3, pp. 213-218, 2001.
120. Y. Chen, Y. Xu, Y. Zhu, and X. Li, "Anti-cancer effects of ginsenoside compound k on pediatric acute myeloid leukemia cells, " Cancer Cell International, vol. 13, article 24, 2013.
121. K. A. Kang, K. H. Lee, S. Chae et al., "Inhibition of telomerase activity in U937 human monocytic leukemia cells by Compound K, a ginseng saponin metabolite, " Biotechnology and Bioprocess Engineering, vol. 11, no. 1, pp. 7-12, 2006.
122. I. K. Lee, K. A. Kang, C. M. Limet al., "CompoundK, ametabolite of ginseng saponin, induces mitochondria-dependent and caspase-dependent apoptosis via the generation of reactive oxygen species in human colon cancer cells, " International Journal ofMolecular Sciences, vol. 11, no. 12, pp. 4916-4931, 2010.
123. A. D. Kim, K. A. Kang, H. S. Kimet al., "A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells, " Cell Death and Disease, vol. 4, no. 8, article e750, 2013.
124. K. A. Kang, H. S. Kim, D. H. Kim, and J. W. Hyun, "The role of a ginseng saponin metabolite as a DNA methyltransferase inhibitor in colorectal cancer cells, " International Journal of Oncology, vol. 43, no. 1, pp. 228-236, 2013.
125. Y.-L. Ming, G. Song, L.-H. Chen et al., "Anti-proliferation and apoptosis induced by a novel intestinal metabolite of ginseng saponin in human hepatocellular carcinoma cells, " Cell Biology International, vol. 31, no. 10, pp. 1265-1273, 2007.
126. D. Y. Kim, M. W. Park, H. D. Yuan, H. J. Lee, S. H. Kim, and S. H. Chung, "Compound K induces apoptosis via CAMKIV/ AMPK pathways in HT-29 colon cancer cells, " Journal of Agricultural and Food Chemistry, vol. 57, no. 22, pp. 10573-10578, 2009.
127. K. A. Kang, M. J. Piao, K. C. Kimet al., "Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity, " International Journal of Oncology, vol. 43, no. 6, pp. 1907-1914, 2013.
128. U. Dougherty, R. Mustafi, Y. Wang et al., "American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR, " BMC Complementary and Alternative Medicine, vol. 11, article 111, 2011.
129. J. A. Hwang, M. K. Hwang, Y. Jang et al., "20-O- -d-glucopyranosyl-20(S)-protopanaxadiol, a metabolite of ginseng, inhibits colon cancer growth by targeting TRPC channelmediated calcium influx, " Journal of Nutritional Biochemistry, vol. 24, no. 6, pp. 1096-1104, 2013.
130. S.-H. Jung, M.-S. Woo, S.-Y. Kim et al., "Ginseng saponin metabolite suppresses phorbol ester-induced matrix metalloproteinase-9 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathways in human astroglioma cells, " International Journal of Cancer, vol. 118, no. 2, pp. 490-497, 2006.
131. Y. Ming, Z. Chen, L. Chen et al., "Ginsenoside compound K attenuates metastatic growth of hepatocellular carcinoma, which is associated with the translocation of nuclear factor- B p65 and reduction of matrix metalloproteinase-2/9, " Planta Medica, vol. 77, no. 5, pp. 428-433, 2011.
132. K.-O. Shin, C.-H. Seo, H.-H. Cho et al., "Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells, " Archives of Pharmacal Research, vol. 37, no. 9, pp. 1183-1192, 2014.
133. H. Hasegawa and M. Uchiyama, "Antimetastatic efficacy of orally administered ginsenoside Rb1 in dependence on intestinal bacterial hydrolyzing potential and significance of treatment with an active bacterial metabolite, " Planta Medica, vol. 64, no. 8, pp. 696-700, 1998.
134. S.-J. Lee, J.-H. Sung, S.-J. Lee, C.-K. Moon, and B.-H. Lee, "Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin, " Cancer Letters, vol. 144, no. 1, pp. 39-43, 1999.
135. S. Chae, K. A. Kang, W. Y. Chang et al., "Effect of compound K, ametabolite of ginseng saponin, combined with -ray radiation in human lung cancer cells in vitro and in vivo, " Journal of Agricultural and Food Chemistry, vol. 57, no. 13, pp. 5777-5782, 2009.
136. Y. Chen, P. Wang, H. Liang, S. Liu, L. Mu, and Y. Zhao, "Therapeutic window alteration of irinotecan by ginsenosides, " Latin American Journal of Pharmacy, vol. 33, no. 10, pp. 1731-1734, 2014.
137. D. G. Lee, S.-I. Jang, Y.-R. Kimet al., "Anti-proliferative effects of ginsenosides extracted frommountain ginseng on lung cancer, " Chinese Journal of Integrative Medicine, 2014.
138. K. W. Leung, L. W. T. Cheung, Y. L. Pon et al., "Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen receptor, " British Journal of Pharmacology, vol. 152, no. 2, pp. 207-215, 2007.
139. Q. H. Zhang, C. F. Wu, J. Y. Yang, Y. H. Mu, X. X. Chen, and Y. Q. Zhao, "Reduction of cyclophosphamide-induced DNA damage and apoptosis effects of ginsenoside Rb1 on mouse bone marrow cells and peripheral blood leukocytes, " Environmental Toxicology and Pharmacology, vol. 27, no. 3, pp. 384-389, 2009.
140. Y. Wang, X. Ye, Z. Ma et al., "Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells, " European Journal of Pharmacology, vol. 601, no. 1-3, pp. 73-78, 2008.
141. J. Fujimoto, H. Sakaguchi, I. Aoki, H. Toyoki, S. Khatun, and T. Tamaya, "Inhibitory effect of ginsenoside-Rb2 on invasiveness of uterine endometrial cancer cells to the basement membrane, " European Journal of Gynaecological Oncology, vol. 22, no. 5, pp. 339-341, 2001.
142. K.-S. Kang, B.-C. Kang, B.-J. Lee et al., "Preventive effect of epicatechin and ginsenoside Rb2 on the inhibition of gap junctional intercellular communication by TPA and H2O2, " Cancer Letters, vol. 152, no. 1, pp. 97-106, 2000.
143. J.-T. Xie, G.-J. Du, E. McEntee et al., "Effects of triterpenoid glycosides from fresh ginseng berry on SW480 human colorectal cancer cell line, " Cancer Research and Treatment, vol. 43, no. 1, pp. 49-55, 2011.
144. F. He, Y. Ding, C. Liang et al., "Antitumor effects of dammaranetype saponins from steamed notoginseng, " Pharmacognosy Magazine, vol. 10, no. 39, pp. 314-317, 2014.
145. H.-H. Aung, S.-R. Mehendale, C.-Z. Wang, J.-T. Xie, E. McEntee, and C.-S. Yuan, "Cisplatin's tumoricidal effect on human breast carcinoma MCF-7 cells was not attenuated by American ginseng, " Cancer Chemotherapy and Pharmacology, vol. 59, no. 3, pp. 369-374, 2007.
146. M. Hao, L. Zhang, Y. Zheng, C. Song, Y. Zhou, and X. Cong, "Anti-proliferative effects of protopanaxadiol-type ginsenosides on human colon epithelial cancer cells, " Journal of Chemical and Pharmaceutical Research, vol. 5, no. 12, pp. 141-144, 2013.
147. L. Berek, D. Szabó, I. B. Petri, Y. Shoyama, Y.-H. Lin, and J. Molnár, "Effects of naturally occurring glucosides, solasodine glucosides, ginsenosides and parishin derivatives on multidrug resistance of lymphoma cells and leukocyte functions, " In Vivo, vol. 15, no. 2, pp. 151-156, 2001.
148. T.-L. Chang, H.-Y. Ding, and Y.-W. Kao, "Role of ginsenoside Rd in inhibiting 26S proteasome activity, " Journal of Agricultural and Food Chemistry, vol. 56, no. 24, pp. 12011-12015, 2008.
149. S. Y. Lee, G. T. Kim, S. H. Roh et al., "Proteome changes related to the anti-cancer activity of HT29 cells by the treatment of ginsenoside Rd, " Pharmazie, vol. 64, no. 4, pp. 242-247, 2009.
150. T. T. Mai, J. Moon, Y. Song et al., "Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells, " Cancer Letters, vol. 321, no. 2, pp. 144-153, 2012.
151. J. Y. Shin, J. M. Lee, H. S. Shin et al., "Anti-cancer effect of ginsenoside F2 against glioblastoma multiforme in xenograft model in SD rats, " Journal of Ginseng Research, vol. 36, no. 1, pp. 86-92, 2012.
152. Y. Han, B. Sun, X. Hu et al., "Transformation of bioactive compounds by Fusarium sacchari fungus isolated from the soilcultivated ginseng, " Journal of Agricultural and FoodChemistry, vol. 55, no. 23, pp. 9373-9379, 2007.
153. N. H. Tung, G. Y. Song, C. Van Minh et al., "Steamed ginsengleaf components enhance cytotoxic effects on human leukemia HL-60 cells, " Chemical and Pharmaceutical Bulletin, vol. 58, no. 8, pp. 1111-1115, 2010.
154. W.-J. Shangguan, H. Li, and Y.-H. Zhang, "Induction of G2/M phase cell cycle arrest and apoptosis by ginsenoside Rf in human osteosarcomaMG-63 cells through the mitochondrial pathway, " Oncology Reports, vol. 31, no. 1, pp. 305-313, 2014.
155. T.-L. Chang, Y.-H. Huang, and Y.-D. Ou, "The role of ginsenosides in inhibiting ubiquitin activating enzyme (E1) activity, " Journal of Functional Foods, vol. 7, no. 1, pp. 462-470, 2014.
156. H.-N. Wang, G.-W. Zuo, C.-L. Li et al., "Effects of ginsenoside Rb1, Rg1 on proliferation of leukemia K562 cells, " Journal of Clinical Rehabilitative Tissue Engineering Research, vol. 13, no. 40, pp. 7829-7832, 2009.
157. J. Xia, J. Li, G.-W. Zuo et al., "The effect of ginsenoside Rg1 on EPOR pathway in leukemia cell line TF-1, " Tumor, vol. 34, no. 2, pp. 113-120, 2014.
158. Z.-H. Fan, K. Isobe, K. Kiuchi, and I. Nakashima, "Enhancement of nitric oxide production fromactivatedmacrophages by a purified form of ginsenoside (Rg1), " The American Journal of Chinese Medicine, vol. 23, no. 3-4, pp. 279-287, 1995.
159. L.-J. Zhang and E.-F. Zhou, "In vitro and in vivo inhibitory effects of ginsenoside Rg1 on proliferation of colon cancer cells, " World Chinese Journal of Digestology, vol. 22, no. 30, pp. 4599-4603, 2014.
160. L. Li, Y. Wang, B. Qi et al., "Suppression of PMA-induced tumor cell invasion and migration by ginsenoside Rg1 via the inhibition of NF- B-dependent MMP-9 expression, " Oncology Reports, vol. 32, no. 5, pp. 1779-1786, 2014.
161. M. Yu, X. Yu, D. Guo et al., "Ginsenoside Rg1 attenuates invasion and migration by inhibiting transforming growth factor-beta1-induced epithelial to mesenchymal transition in HepG2 cells, " Molecular Medicine Reports, vol. 11, no. 4, pp. 3167-3173, 2015.
162. T.-H. Zhao, "Enhancing effect of ginsenoside Rg1 on LAK cells antitumor activity in vitro, " Chinese Journal of Clinical Oncology, vol. 21, no. 1, pp. 48-49, 1994.
163. Y.-N. Lee, H.-Y. Lee, Y. M. Lee et al., "Involvement of glucocorticoid receptor in the induction of differentiation by ginsenosides in F9 teratocarcinoma cells, "The Journal of Steroid Biochemistry and Molecular Biology, vol. 67, no. 2, pp. 105-111, 1998.
164. J.-H. Yoon, Y.-J. Choi, and S.-G. Lee, "Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 andmitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells, " European Journal of Pharmacology, vol. 679, no. 1-3, pp. 24-33, 2012.
165. J.-S. Jung, J.-H. Ahn, T.-K. Le, D.-H. Kim, and H.-S. Kim, "Protopanaxatriol ginsenoside Rh1 inhibits the expression of matrix metalloproteinases and the in vitro invasion/migration of human astroglioma cells, " Neurochemistry International, vol. 63, no. 2, pp. 80-86, 2013.
166. L. Xu, B. Wang, and J. Gao, "Preliminary studies of notoginsenoside R1-induced differentiation of HL-60 cell lines in vitro, " Journal ofWest China University ofMedical Sciences, vol. 22, no. 2, pp. 124-127, 1991.
167. C.-Z. Wang, J.-T. Xie, B. Zhang et al., "Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells, " International Journal of Oncology, vol. 31, no. 5, pp. 1149-1156, 2007.
168. D. G. Popovich and D. D. Kitts, "Ginsenosides 20(S)-protopanaxadiol and Rh2 reduce cell proliferation and increase sub-G1 cells in two cultured intestinal cell lines, Int-407 andCaco-2, " Canadian Journal of Physiology and Pharmacology, vol. 82, no. 3, pp. 183-190, 2004.
169. H. Hasegawa, R. Suzuki, T. Nagaoka, Y. Tezuka, S. Kadota, and I. Saiki, "Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol, " Biological and Pharmaceutical Bulletin, vol. 25, no. 7, pp. 861-866, 2002.
170. H. Hasegawa, J.-H. Sung, S. Matsumiya et al., "Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids, " Planta Medica, vol. 61, no. 5, pp. 409-413, 1995.
171. Y. Sun, H. Lin, Y. Zhu et al., "A randomized, prospective, multicentre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients, " Chinese Journal of Lung Cancer, vol. 9, no. 3, pp. 254-258, 2006.
172. Z.-J. Chen, J. Cheng, Y.-P. Huang et al., "Effect of adjuvant chemotherapy of ginsenoside Rg3 combined withmitomycin C and tegafur in advanced gastric cancer, " Zhonghua Wei Chang Wai Ke Za Zhi, vol. 10, no. 1, pp. 64-66, 2007.
173. J.-Y. Huang, Y. Sun, Q.-X. Fan, and Y.-Q. Zhang, "Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: a randomized controlled trial, " Zhong Xi Yi JieHe Xue Bao, vol. 7, no. 11, pp. 1047-1051, 2009.
174. Y. Yu, C. Zhang, L. Liu, and X. Li, "Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas, " Experimental and Therapeutic Medicine, vol. 5, no. 3, pp. 761-766, 2013.
175. Q. Zhang, X. Kang, B. Yang, J. Wang, and F. Yang, "Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice, " Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 5, pp. 647-653, 2008.
176. X. Huang, M. Hou, C. Yi, and H. Song, "Anti-angiogenic effects of low-dose gemcitabine combined with ginsenoside Rg3 on mouse Lewis lung carcinoma, " Chinese Journal of Lung Cancer, vol. 9, no. 2, pp. 132-136, 2006.
177. J. Cathcart, A. Pulkoski-Gross, and J. Cao, "Targeting matrix metalloproteinases in cancer: bringing new life to old ideas, " Genes & Diseases, vol. 2, no. 1, pp. 26-34, 2015.
178. Y.-J. Kim, W.-I. Choi, B.-N. Jeon et al., "Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-beta1-induced epithelialmesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance, " Toxicology, vol. 322, pp. 23-33, 2014.
179. S. G. Lee, Y. J. Kang, and J.-O. Nam, "Anti-metastasis effects of ginsenoside Rg3 in B16F10 cells, " Journal of Microbiology and Biotechnology, vol. 25, no. 12, pp. 1997-2006, 2015.
180. N. Guan, X. Huo, Z. Zhang, S. Zhang, J. Luo, and W. Guo, "Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13, " Tumor Biology, vol. 36, no. 9, pp. 6789-6795, 2015.
181. B. Zhou, J. Wang, and Z. Yan, "Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model, " OncoTargets andTherapy, vol. 7, pp. 1945-1954, 2014.
182. R. Wang, Y. Li, W. Wang, M. Zhou, and Z. Cao, "Compound K suppresses myeloid-derived suppressor cells in a mouse model bearing CT26 colorectal cancer xenograft, " Journal of Southern Medical University, vol. 35, no. 5, pp. 748-752, 2015.
183. Y. Hao, P. Wang, J. Wu, and Q.-Y. Qiu, "Effects of ginsenoside and berberine on secretion of immunosuppressive cytokines in lung carcinoma cell line PG, " Zhong Xi Yi JieHeXue Bao, vol. 6, no. 3, pp. 278-282, 2008.
184. W. Zhou, M.-Q. Feng, X.-W. Li et al., "X-ray structure investigation of (20S)-20-O- -D-glucopyranosyl-protopanaxadiol and antitumor effect on Lewis lung carcinoma in vivo, " Chemistry & Biodiversity, vol. 6, pp. 380-388, 2009.
185. H. Hasegawa and I. Saiki, "Oleoyl triterpene glycoside biotransformed from ginseng suppresses growth and metastasis of murine B16-F10 melanoma via immunostimulation, " Wakan Iyakugaku Zasshi, vol. 17, no. 5, pp. 186-193, 2000.
186. I. Mellman and R.-M. Steinman, "Dendritic cells: specialized and regulated antigen processing machines, " Cell, vol. 106, no. 3, pp. 255-258, 2001.
187. M. Takei, E. Tachikawa, and A. Umeyama, "Dendritic cells promoted by ginseng saponins drive a potentTh1 polarization, " Biomarker Insights, vol. 3, pp. 269-286, 2008.
188. M. Takei, E. Tachikawa, H. Hasegawa, and J.-J. Lee, "Dendritic cells maturation promoted by M1 and M4, end products of steroidal ginseng saponinsmetabolized in digestive tracts, drive a potent Th1 polarization, " Biochemical Pharmacology, vol. 68, no. 3, pp. 441-452, 2004.
189. A. Y. Jang, E. J. Song, S. H. Shin et al., "Potentiation of natural killer (NK) cell activity by methanol extract of cultured cambial meristematic cells of wild ginseng and its mechanism, " Life Sciences, vol. 135, pp. 138-146, 2015.
190. J. Li, T. Liu, L. Zhao et al., "Ginsenoside 20(S)Rg3 inhibits the Warburg effect through STAT3 pathways in ovarian cancer cells, " International Journal of Oncology, vol. 46, no. 2, pp. 775-781, 2015.
191. Y.-M. Jeong, W.-K. Oh, T.-L. Tran et al., "Aglycone of Rh4 inhibits melanin synthesis in B16 melanoma cells: possible involvement of the protein kinase A pathway, " Bioscience, Biotechnology, and Biochemistry, vol. 77, no. 1, pp. 119-125, 2013.
192. E. Chung, K.-Y. Lee, Y.-J. Lee, Y.-H. Lee, and S.-K. Lee, "Ginsenoside-Rg1 down-regulates glucocorticoid receptor and displays synergistic effects with cAMP, " Steroids, vol. 63, no. 7-8, pp. 421-424, 1998.
193. H.-D. Yuan, H.-Y. Quan, Y. Zhang, S.-H. Kim, and S.-H. Chung, "20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway, " Molecular Medicine Reports, vol. 3, no. 5, pp. 825-831, 2010.
194. X. Dolcet, D. Llobet, J. Pallares, and X. Matias-Guiu, "NF- B in development and progression of human cancer, " Virchows Archiv, vol. 446, no. 5, pp. 475-482, 2005.
195. J.-Y. Lee, J.-W. Shin, K.-S. Chun et al., "Antitumor promotional effects of a novel intestinal bacterialmetabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin, " Carcinogenesis, vol. 26, no. 2, pp. 359-367, 2005.
196. T.-K. Yun, S.-H. Kim, and Y.-S. Lee, "Trial of a new mediumterm model using benzo(a)pyrene induced lung tumor in newborn mice, " Anticancer Research, vol. 15, no. 3, pp. 839-845, 1995.
197. H. Hasegawa and Y. Benno, "Anticarcinogenesis in mice by ginseng-hydrolyzing colonic bacteria, " Microbial Ecology in Health and Disease, vol. 12, no. 2, pp. 85-91, 2000.
198. L.-S. Lee, K.-K. Stephenson, J.-W. Fahey et al., "Induction of chemoprotective phase 2 enzymes by ginseng and its components, " Planta Medica, vol. 75, pp. 1129-1133, 2009.
199. C.-H. Choi, G. Kang, and Y.-D. Min, "Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from korean red ginseng, " Planta Medica, vol. 69, no. 3, pp. 235-240, 2003.
200. S. Kitagawa, T. Takahashi, T. Nabekura, E. Tachikawa, and H. Hasegawa, "Inhibitory effects of ginsenosides and their hydrolyzed metabolites on daunorubicin transport in KB-C2 cells, " Biological & Pharmaceutical Bulletin, vol. 30, no. 10, pp. 1979-1981, 2007.